FDA Proposed Rule Establishes Criteria for Difficult Drugs to Compound Under Sections 503A and 503B (JSON)

lexblog.com/lib/9YCNS1HCview recordjson

{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "FDA Proposed Rule Establishes Criteria for Difficult Drugs to Compound Under Sections 503A and 503B",
    "url": "https://www.lexblog.com/2024/04/02/fda-proposed-rule-establishes-criteria-for-difficult-drugs-to-compound-under-sections-503a-and-503b/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-9YCNS1HC",
        "url": "https://www.lexblog.com/lib/9YCNS1HC/"
    },
    "datePublished": "2024-04-02T12:13:35-04:00",
    "dateModified": "2024-04-02T09:14:44-04:00",
    "author": {
        "@type": "Person",
        "name": "Rachael G. Pontikes, Emily L. Hussey, Kelly Kearney, Susan Dewey, Amica Nesbitt, Madhav Bhatt"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Reed Smith LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Health Industry Washington Watch",
    "about": "Food, Drug & Agriculture",
    "sourceUrl": "https://www.healthindustrywashingtonwatch.com/?p=26253",
    "sourceStability": "may-move"
}